CO2019014840A2 - Vectores aav auto reguladores para la expresion segura de mecp2 en sidrome de rett - Google Patents
Vectores aav auto reguladores para la expresion segura de mecp2 en sidrome de rettInfo
- Publication number
- CO2019014840A2 CO2019014840A2 CONC2019/0014840A CO2019014840A CO2019014840A2 CO 2019014840 A2 CO2019014840 A2 CO 2019014840A2 CO 2019014840 A CO2019014840 A CO 2019014840A CO 2019014840 A2 CO2019014840 A2 CO 2019014840A2
- Authority
- CO
- Colombia
- Prior art keywords
- self
- mecp2
- rett syndrome
- regulatory
- aav vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762516060P | 2017-06-06 | 2017-06-06 | |
| PCT/US2018/036200 WO2018226785A1 (en) | 2017-06-06 | 2018-06-06 | Self-regulating aav vectors for safe expression of mecp2 in rett syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019014840A2 true CO2019014840A2 (es) | 2020-01-17 |
Family
ID=64567243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0014840A CO2019014840A2 (es) | 2017-06-06 | 2019-12-27 | Vectores aav auto reguladores para la expresion segura de mecp2 en sidrome de rett |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11680275B2 (https=) |
| EP (1) | EP3635122A4 (https=) |
| JP (2) | JP2020522269A (https=) |
| KR (1) | KR20200015701A (https=) |
| CN (1) | CN111065742A (https=) |
| AU (1) | AU2018281145A1 (https=) |
| BR (1) | BR112019025732A2 (https=) |
| CA (1) | CA3066623A1 (https=) |
| CL (1) | CL2019003582A1 (https=) |
| CO (1) | CO2019014840A2 (https=) |
| EA (1) | EA201992882A1 (https=) |
| IL (1) | IL271170A (https=) |
| MX (1) | MX2019014760A (https=) |
| SG (1) | SG11201911737PA (https=) |
| WO (1) | WO2018226785A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
| EP3256170B1 (en) | 2015-02-13 | 2020-09-23 | University of Massachusetts | Compositions and methods for transient delivery of nucleases |
| JP7106534B2 (ja) * | 2016-11-17 | 2022-07-26 | ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
| JP7618386B2 (ja) | 2017-01-30 | 2025-01-21 | ブレインヴェクティス | ポリグルタミン反復脊髄小脳失調症の処置におけるコレステロール２４－ヒドロキシラーゼ（ｈｙｄｒｏｌａｓｅ）のための発現ベクター |
| AU2019247748A1 (en) | 2018-04-03 | 2020-10-08 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
| EP3774852A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Antibody-evading virus vectors |
| MX2020010465A (es) | 2018-04-03 | 2021-01-08 | Vectores de virus para direccionamiento a tejidos oftalmicos. | |
| CN113166208B (zh) | 2018-10-02 | 2024-11-22 | 沃雅戈治疗公司 | 重新定向aav衣壳的嗜性 |
| AR118465A1 (es) | 2019-03-21 | 2021-10-06 | Stridebio Inc | Vectores de virus adenoasociados recombinantes |
| CA3133889A1 (en) * | 2019-04-24 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
| JP7624410B2 (ja) * | 2019-05-21 | 2025-01-30 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | レット症候群の治療におけるコレステロール ２４－ヒドロラーゼのための発現ベクター |
| US12611436B2 (en) | 2019-10-17 | 2026-04-28 | Sarepta Therapeutics, Inc. | AAV transfer cassette |
| JP2022551739A (ja) | 2019-10-17 | 2022-12-13 | ストライドバイオ，インコーポレイテッド | ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター |
| EP4065600A1 (en) | 2019-11-25 | 2022-10-05 | Cornell University | Apoe gene therapy |
| JP7702949B2 (ja) * | 2019-12-05 | 2025-07-04 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | ヒトｍｅｃｐ２遺伝子を発現するように設計されたトランスジーンカセット |
| US12497612B2 (en) | 2020-03-09 | 2025-12-16 | University Of Massachusetts | Gene replacement therapy for FOXG1 syndrome |
| MX2022014258A (es) * | 2020-05-12 | 2023-02-22 | Univ Pennsylvania | Composiciones para la reducción específica de un fármaco de la expresión de transgén. |
| TWI900553B (zh) | 2020-05-13 | 2025-10-11 | 美商航海家醫療公司 | Aav蛋白殼之趨性重定向 |
| MX2023000124A (es) * | 2020-06-30 | 2023-03-08 | Univ Court Univ Of Edinburgh | Sistema de expresion de transgenes. |
| AU2021328475A1 (en) * | 2020-08-19 | 2023-03-16 | Sarepta Therapeutics, Inc. | Adeno-associated virus vectors for treatment of Rett syndrome |
| CN113754727B (zh) * | 2020-09-30 | 2022-07-12 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| WO2022094078A1 (en) * | 2020-10-28 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
| EP4426716A1 (en) | 2021-11-02 | 2024-09-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| GB202201242D0 (en) * | 2022-01-31 | 2022-03-16 | Univ Edinburgh | Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders |
| CN121219020A (zh) * | 2023-03-22 | 2025-12-26 | 圣拉斐尔医院有限责任公司 | 基因疗法 |
| EP4715058A1 (en) * | 2023-05-15 | 2026-03-25 | Genecombio Ltd. | Gene therapy for rett syndrome |
| CN119101681A (zh) * | 2023-06-09 | 2024-12-10 | 仁景(苏州)生物科技有限公司 | 表达可调控的工程化rna分子 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| US20040106566A1 (en) * | 2002-05-17 | 2004-06-03 | Shi-Lung Lin | RNA-splicing and processing-directed gene silencing and the relative applications thereof |
| EP2214706A1 (en) | 2007-10-23 | 2010-08-11 | Novartis AG | Use of trkb antibodies for the treatment of respiratory disorders |
| PE20091326A1 (es) | 2008-01-17 | 2009-09-18 | Irm Llc | Anticuerpos anti-trkb mejorados |
| WO2010105096A2 (en) | 2009-03-11 | 2010-09-16 | University Of Massachusetts | Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212) |
| WO2012055826A1 (en) | 2010-10-25 | 2012-05-03 | Universite De La Mediterranee (Aix-Marseille Ii) | TREATMENT OF MeCP2-ASSOCIATED DISORDERS |
| US20160000794A1 (en) | 2012-09-25 | 2016-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Methods for the diagnosis and treatment of sjogren's syndrome |
| ES2739288T3 (es) | 2013-09-13 | 2020-01-30 | California Inst Of Techn | Recuperación selectiva |
| US10072251B2 (en) | 2014-02-19 | 2018-09-11 | University Of Massachusetts | Recombinant AAVS having useful transcytosis properties |
| WO2015164786A1 (en) | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
| US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
| EP3200830B1 (en) | 2014-10-03 | 2020-09-09 | University of Massachusetts | High efficiency library-identified aav vectors |
| CN107073051B (zh) | 2014-10-21 | 2021-08-24 | 马萨诸塞大学 | 重组aav变体及其用途 |
| US11046955B2 (en) | 2015-04-24 | 2021-06-29 | University Of Massachusetts | Modified AAV constructs and uses thereof |
| EP3121284A1 (en) | 2015-07-22 | 2017-01-25 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Bicistronic aav vector for rna interference in als |
-
2018
- 2018-06-06 US US16/619,733 patent/US11680275B2/en active Active
- 2018-06-06 EA EA201992882A patent/EA201992882A1/ru unknown
- 2018-06-06 AU AU2018281145A patent/AU2018281145A1/en not_active Abandoned
- 2018-06-06 BR BR112019025732-2A patent/BR112019025732A2/pt not_active IP Right Cessation
- 2018-06-06 KR KR1020207000120A patent/KR20200015701A/ko not_active Ceased
- 2018-06-06 CN CN201880051148.4A patent/CN111065742A/zh active Pending
- 2018-06-06 SG SG11201911737PA patent/SG11201911737PA/en unknown
- 2018-06-06 WO PCT/US2018/036200 patent/WO2018226785A1/en not_active Ceased
- 2018-06-06 MX MX2019014760A patent/MX2019014760A/es unknown
- 2018-06-06 JP JP2019567677A patent/JP2020522269A/ja active Pending
- 2018-06-06 CA CA3066623A patent/CA3066623A1/en active Pending
- 2018-06-06 EP EP18812887.0A patent/EP3635122A4/en active Pending
-
2019
- 2019-12-04 IL IL271170A patent/IL271170A/en unknown
- 2019-12-06 CL CL2019003582A patent/CL2019003582A1/es unknown
- 2019-12-27 CO CONC2019/0014840A patent/CO2019014840A2/es unknown
-
2023
- 2023-05-03 US US18/311,367 patent/US20230416779A1/en active Pending
- 2023-08-23 JP JP2023135189A patent/JP2023164447A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023164447A (ja) | 2023-11-10 |
| CL2019003582A1 (es) | 2020-09-25 |
| EP3635122A4 (en) | 2021-03-31 |
| MX2019014760A (es) | 2020-08-03 |
| KR20200015701A (ko) | 2020-02-12 |
| CN111065742A (zh) | 2020-04-24 |
| EA201992882A1 (ru) | 2020-05-25 |
| US20200181646A1 (en) | 2020-06-11 |
| JP2020522269A (ja) | 2020-07-30 |
| BR112019025732A2 (pt) | 2020-06-30 |
| US11680275B2 (en) | 2023-06-20 |
| EP3635122A1 (en) | 2020-04-15 |
| AU2018281145A1 (en) | 2020-01-02 |
| SG11201911737PA (en) | 2020-01-30 |
| WO2018226785A1 (en) | 2018-12-13 |
| IL271170A (en) | 2020-01-30 |
| CA3066623A1 (en) | 2019-12-13 |
| US20230416779A1 (en) | 2023-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019014840A2 (es) | Vectores aav auto reguladores para la expresion segura de mecp2 en sidrome de rett | |
| BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
| CO2018012096A2 (es) | Proteínas de fusión gdf15 y usos de estas | |
| CL2018000740A1 (es) | Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden | |
| CL2023001338A1 (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
| CO2021006362A2 (es) | Construcciones de ácido nucleico y métodos de uso | |
| SA520412637B1 (ar) | B7 الفيروس الغدي الحال للورم المشفِّر لبروتين | |
| CL2018001107A1 (es) | Variantes del factor viii cpg reducido, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasis. | |
| MX388264B (es) | Suministro mejorado de particulas virales al cuerpo estriado y al cortex. | |
| MX2017010117A (es) | Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso. | |
| EP4659816A3 (en) | MODIFIED CAPSID PROTEINS FOR IMPROVED PARVOVIRUS VECTOR DELIVERY | |
| CR20170174A (es) | Composiciones y métodos para el silenciamiento de la expresión cénica del virus de la hepatitis b | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| BR112016018100A2 (pt) | acoplador antigênico de células t trifuncional, métodos e usos do mesmo | |
| AR102006A1 (es) | Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos | |
| PE20200722A1 (es) | Metodos de terapia genica del factor viii (fviii) | |
| MX2016009149A (es) | Variantes mejoradas de enzimas. | |
| ECSP22049014A (es) | Variantes de progranulina | |
| MX2017007103A (es) | Variantes de lipasa y polinucleotidos que las codifican. | |
| AR123756A1 (es) | Construcciones de ácidos nucléicos, vectores virales y partículas virales | |
| PE20211235A1 (es) | Variantes de lfa3 y composiciones y usos de las mismas | |
| AR104252A1 (es) | Promotor de plantas para expresión transgénica | |
| AR121381A2 (es) | Composición farmacéutica que comprende moduladores de actividad complementaria y dispositivo autoinyector | |
| AR104256A1 (es) | Polipéptido que comprende un epitope de la proteína e del virus del dengue, polinucleótido y constructo genético que lo codifican, partículas similares a virus (vlps) que comprenden dicho polipéptido, célula transgénica que las expresa, vacunas y método para tratar el dengue |